What Experts Think About Prostate Cancer Management During the COVID-19 Pandemic: Report from the Advanced Prostate Cancer Consensus Conference 2021.
COVID-19 boost injection
COVID-19 pandemic
COVID-19 vaccine
Prostate cancer
Prostate cancer management
Telemedicine
Journal
European urology
ISSN: 1873-7560
Titre abrégé: Eur Urol
Pays: Switzerland
ID NLM: 7512719
Informations de publication
Date de publication:
07 2022
07 2022
Historique:
received:
21
01
2022
accepted:
04
02
2022
pubmed:
9
4
2022
medline:
15
6
2022
entrez:
8
4
2022
Statut:
ppublish
Résumé
Patients with advanced prostate cancer (APC) may be at greater risk for severe illness, hospitalisation, or death from coronavirus disease 2019 (COVID-19) due to male gender, older age, potential immunosuppressive treatments, or comorbidities. Thus, the optimal management of APC patients during the COVID-19 pandemic is complex. In October 2021, during the Advanced Prostate Cancer Consensus Conference (APCCC) 2021, the 73 voting members of the panel members discussed and voted on 13 questions on this topic that could help clinicians make treatment choices during the pandemic. There was a consensus for full COVID-19 vaccination and booster injection in APC patients. Furthermore, the voting results indicate that the expert's treatment recommendations are influenced by the vaccination status: the COVID-19 pandemic altered management of APC patients for 70% of the panellists before the vaccination was available but only for 25% of panellists for fully vaccinated patients. Most experts (71%) were less likely to use docetaxel and abiraterone in unvaccinated patients with metastatic hormone-sensitive prostate cancer. For fully vaccinated patients with high-risk localised prostate cancer, there was a consensus (77%) to follow the usual treatment schedule, whereas in unvaccinated patients, 55% of the panel members voted for deferring radiation therapy. Finally, there was a strong consensus for the use of telemedicine for monitoring APC patients. PATIENT SUMMARY: In the Advanced Prostate Cancer Consensus Conference 2021, the panellists reached a consensus regarding the recommendation of the COVID-19 vaccine in prostate cancer patients and use of telemedicine for monitoring these patients.
Identifiants
pubmed: 35393158
pii: S0302-2838(22)01650-5
doi: 10.1016/j.eururo.2022.02.010
pmc: PMC8849852
pii:
doi:
Substances chimiques
Androgen Antagonists
0
COVID-19 Vaccines
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
6-11Subventions
Organisme : Medical Research Council
ID : MC_UU_00004/02
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_UU_00004/08
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_UU_12023/28
Pays : United Kingdom
Commentaires et corrections
Type : CommentIn
Type : ErratumIn
Type : CommentIn
Informations de copyright
Copyright © 2022 The Authors. Published by Elsevier B.V. All rights reserved.
Références
Crit Rev Oncol Hematol. 2021 Nov;167:103491
pubmed: 34626792
Eur Urol. 2020 Jun;77(6):667-668
pubmed: 32312544
Ann Oncol. 2020 Aug;31(8):1040-1045
pubmed: 32387456
Vaccines (Basel). 2021 Sep 20;9(9):
pubmed: 34579285
Eur Urol. 2020 Nov;78(5):731-742
pubmed: 32893062
N Engl J Med. 2021 Oct 7;385(15):1393-1400
pubmed: 34525275
Eur Urol. 2015 May;67(5):825-36
pubmed: 25097095
Crit Rev Oncol Hematol. 2021 Jan;157:103129
pubmed: 33227573
Eur Urol. 2021 Feb;79(2):263-282
pubmed: 33039206
World J Urol. 2022 Apr;40(4):907-914
pubmed: 34477955